Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Clinton Yam, MBBS, Daniel J. Landsburg, MD, Xinyi Lin, PhD, Anthony Mato, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Noelle Frey, MD, Edward A. Stadtmauer, MD, David Porter, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2015) 126 (23): 3183.

https://doi.org/10.1182/blood.V126.23.3183.3183

Published: 2015

Journal Articles

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Clinton Yam, MBBS, Lisa Crisalli, BS, Selina Luger, MD, Alison Loren, MD MS, Elizabeth O Hexner, MD, Noelle Frey, MD, James Mangan, MD PhD, Amy Gao, MS, Edward A. Stadtmauer, MD, David Porter, MD, Ran Reshef, MD

Blood (2015) 126 (23): 4380.

https://doi.org/10.1182/blood.V126.23.4380.4380

Published: 2015

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Blood (2015) 126 (23): 719.

https://doi.org/10.1182/blood.V126.23.719.719

Published: 2015

Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD

Blood (2015) 126 (23): 2929.

https://doi.org/10.1182/blood.V126.23.2929.2929

Published: 2015

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

Journal Articles

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Anthony R. Mato, MD MSCE, Kenneth A. Foon, MD, Tatyana Feldman, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kar Fai Chow, MD, Marisa Valentinetti, BS, Mary Morin, BS, Kelly Azzollini, BS, Gabriella Magarelli, MS, Pritish K. Bhattacharyya, MD, Joshua Zenreich, BS, Christina Howlett, PharmD, BCOP, Lauren-Nicole Pascual, BS, Kara Yanotti, BSN, Sabrina Kdiry, BSN, David Porter, MD, Andre Goy, MD

Blood (2014) 124 (21): 4678.

https://doi.org/10.1182/blood.V124.21.4678.4678

Published: 2014

Journal Articles

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Jingmei Hsu, MD PhD, Anita J. Kumar, MDMS, Martin P. Carroll, MD, Noelle V. Frey, MDMS, Nirav N. Shah, MD, Zhao Jianhua, PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, James K. Mangan, MDPhD, Alexander E. Perl, MD, David Porter, MD, Jennifer Morrissette, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2343.

https://doi.org/10.1182/blood.V124.21.2343.2343

Published: 2014

Journal Articles

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Alexis Zebrowski, BA, Alexandra Hanlon, PhD, James Mangan, MD PhD, Jennifer Pinto-Martin, PhD MPH, Selina M. Luger, MD, Alison W. Loren, MD, Elizabeth O Hexner, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 1239.

https://doi.org/10.1182/blood.V124.21.1239.1239

Published: 2014

Journal Articles

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Vijay Bhoj, MD PhD, Michael C Milone, MD PhD, Carl H. June, MD, David Porter, MD, Stephan A. Grupp, MD PhD, Jan J Melenhorst, PhD, Simon F. Lacey, PhD BSc, Colleen Callahan, MSN, CRNP, James Capobianchi, Gerald Wertheim, MDPhD, Yolanda Mahnke, PhD

Blood (2014) 124 (21): 1110.

https://doi.org/10.1182/blood.V124.21.1110.1110

Published: 2014

Journal Articles

Evolution to Plasmablastic Lymphoma (PBL) after CAR-T Cell Therapy in a Case of SLL/CLL with Richter’s Transformation

Andrew Evans, MDPhD, Richard Burack, MDPhD, Paul G. Rothberg, PhD, David Porter, MD, Jane L. Liesveld, MD

Blood (2014) 124 (21): 5660.

https://doi.org/10.1182/blood.V124.21.5660.5660

Published: 2014

Journal Articles

Provider Based Outcomes on an Allogeneic Transplant Service

Nirav N. Shah, MD, Colleen Kucharczuk, CRNP, Nandita Mitra, PhD, Rebecca Hirsh, MD, Jakub Svoboda, MD, David Porter, MD, Alison W. Loren, MDMS, Noelle V. Frey, MDMS, Marilyn M. Schapira, MD MPH

Blood (2014) 124 (21): 2643.

https://doi.org/10.1182/blood.V124.21.2643.2643

Published: 2014

Journal Articles

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, MDMS, Bruce L. Levine, PhD, Simon F. Lacey, PhD BSc, Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Stephen J. Schuster, MD, Pamela Shaw, PhD, Wei-Ting Hwang, PhD, Mariusz A. Wasik, MD, Amrom Obstfeld, MD, Mimi Leung, MPH, Angela Shen, MD, Solveig G. Ericson, MD PhD, Jan J Melenhorst, PhD, Carl H. June, MD, David Porter, MD

Blood (2014) 124 (21): 2296.

https://doi.org/10.1182/blood.V124.21.2296.2296

Published: 2014

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

Impact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies

Robert J Soiffer, MD, Jennifer LeRademacher, PhD, Vincent T Ho, MD, Fangyu Kan, MD, MS, Andrew Artz, MD, MS, Richard Champlin, Steven Devine, MD, Hillard M. Lazarus, MD, FACP, David I Marks, MB, BS, PHD, David Porter, MD, Edmund K. Waller, MD, PhD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS

Blood (2010) 116 (21): 2305.

https://doi.org/10.1182/blood.V116.21.2305.2305

Published: 2010

Journal Articles

Risk Factors for Venous Thromboembolism In Hospitalized Cancer Patients with Central Catheters

Emma C. Scott, MD, Kathryn Schmidt Hudson, MD, Scott Trerotola, MD, Heather Smith, PT, MPH, David Porter, MD, Suman L. Sood, MD

Blood (2010) 116 (21): 810.

https://doi.org/10.1182/blood.V116.21.810.810

Published: 2010

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Aziz Nazha, MD, Rachel Cook, MS, MD, Dan T. Vogl, MD, Patricia A. Mangan, APRN, BC, Kimberly Hummel, Kathleen Cunningham, Selina Luger, MD, David Porter, MD, Stephen J. Schuster, MD, Una O'Doherty, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A. Stadtmauer, MD

Blood (2009) 114 (22): 2146.

https://doi.org/10.1182/blood.V114.22.2146.2146

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

NARROW

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Evolution to Plasmablastic Lymphoma (PBL) after CAR-T Cell Therapy in a Case of SLL/CLL with Richter’s Transformation

Provider Based Outcomes on an Allogeneic Transplant Service

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Risk Factors for Venous Thromboembolism In Hospitalized Cancer Patients with Central Catheters

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only